Reirradiation of lung, breast and bone tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique

The process of reirradiation in oncology presents a distinctive set of challenges, wherein clinical decision-making is predicated on a delicate balancing act between the efficacy of the treatment and the risk of severe toxicity. Despite the paucity of randomised and prospective data, there is an increasing number of data encouraging its consideration for patients with local or metastatic recurrence. While awaiting dedicated guidance from international scientific societies, this publication is based on multicentre reflections of the "Recommendations Commission" of the Société française de radiothérapie oncologique (the French society for radiation oncology). It addresses key questions related to reirradiation, with a particular focus on lung, breast and bone tumours.

Published by Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2025. The guideline itself is at the source linked here.

doi.org/10.1016/j.canrad.2025.104780